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Abstract: The insulin-like growth factor receptor is a potential 
target in small-cell lung cancer. We conducted a phase I study of 
cisplatin, etoposide plus dalotuzumab. Two dose levels of dalo-
tuzumab (DL1 5mg/kg, DL2 10mg/kg IV weekly) were evalu-
ated in combination with cisplatin (25mg/m2) and etoposide 
(100mg/m2) IV D1-3, every 21 days, for patients with chemother-
apy-naive  extensive-stage small-cell lung cancer. Primary outcome 
was determination of the recommended phase 2 dose. Secondary 
outcomes included response rate and toxicity. Twelve patients were 
treated (DL1, 3 and DL2, 9). The median age was 63 years (48–70), 
with six males and six females. The majority of patients were Eastern 
Cooperative Oncology Group1 and had four or more sites of disease. 
No  dose-limiting toxicities were observed in DL1 or DL2, although 
one patient died from neutropenic sepsis in an expanded cohort at 
DL2. The recommended phase 2 dose of dalotuzumab was 10mg/
kg/week. The confirmed objective response rate was 67% (partial 
response 8, stable disease 2, progressive disease 1, nonevaluable 
1). Grade 3 or higher toxicities (any cycle) occurring in more than 
one patient included: neutropenia (92%); thrombocytopenia (25%); 
leukopenia (50%); anemia (17%); fatigue (33%); joint pain (17%); 
thrombosis (25%). Grade 2 or 3 hyperglycemia was observed in 
one of three (DL1) and five of nine (DL2) patients. Eight serious 
adverse events (thrombosis, febrile neutropenia, infection, syncope, 
fatigue [2], dyspnea, back pain) were observed in three patients. 
Dalotuzumab can be combined at full dose with standard doses of 
cisplatin and etoposide. The observed toxicities are consistent with 
that expected from cisplatin and etoposide except for hyperglyce-
mia, which seems to be dose dependent.
Key Words: Small-cell lung cancer, Chemotherapy, Insulin-like 
growth factor, Monoclonal antibody, Phase I clinical trial.
(J Thorac Oncol. 2014;9: 410–413)
Small-cell lung cancer (SCLC) represents approximately 15% of all lung cancers, representing 34,000 cases and 
29,000 deaths annually in the United States.1 Although recent 
recommendations from the International Association for the 
Study of Lung Cancer suggest Tumor Node Metastasis staging 
provides better prognostic information,2 a simplified approach 
to staging, based on the presence (extensive-stage [ES]) or 
absence (limited-stage) of disease outside of the thorax, is 
still commonly used. Little progress has been made though, in 
systemic treatment and outcomes for ES SCLC.3 A variety of 
strategies have been evaluated over the last 15 years including 
the use of non–cross-resistant chemotherapy,4 intense weekly 
chemotherapy,5 maintenance chemotherapy6 and high-dose 
chemotherapy with transplantation.7 However, none of these 
strategies have resulted in clear improvements in survival for 
patients with SCLC.
Additional research has focused on targeted approaches, 
since multiple molecular abnormalities have been documented 
in SCLC tumors.8 However, the evaluation of targeted thera-
pies in this malignancy has, to date, been unrewarding. Trials 
evaluating antiangiogenic agents, matrix metalloproteinase 
inhibitors, inhibition of c-myc with imatinib, B cell lymphoma 
2 (BCL-2) antisense therapy, and proteosome inhibition with 
bortezomib have all proven ineffective.8
One promising research target for SCLC is the 
 insulin-like growth factor receptor (IGF-R) pathway. In vitro 
and in vivo data support a role for serum IGF,9 as well as 
IGF-1 and IGF-2 gene expression in SCLC.10 Dalotuzumab 
(MK-0646; Merck, Whitehouse Station, NJ) is a recombi-
nant IgG1 monoclonal antibody against the IGF-1R, with 
potential for  antibody-directed cell-mediated cytotoxicity.11 
Single-agent phase I studies have shown dalotuzumab to 
be safe and well tolerated. The recommended phase II dose 
was determined to be 10mg/kg once weekly by intravenous 
(IV) infusion. Given the preclinical rationale, we conducted 
a phase I trial of dalotuzumab in combination with cisplatin 
and etoposide in patients with ES SCLC.
PATIENTS AND METHODS
Eligible patients had ES SCLC, amenable to 
 platinum-based chemotherapy, measurable disease, no prior 
chemotherapy, Eastern Cooperative Oncology Group perfor-
mance status 0 to 2, adequate hematological and biochemical 
Copyright © 2013 by the International Association for the Study of Lung 
Cancer
ISSN: 1556-0864/14/0903-0410
NCIC CTG IND.190 Phase I Trial of Dalotuzumab  
 (MK-0646) in Combination with Cisplatin and  
Etoposide in Extensive-Stage Small-Cell Lung Cancer
Peter M. Ellis, MD, PhD,* Frances A. Shepherd, MD,† Scott A. Laurie, MD,‡ Glenwood D. Goss, MD,‡  
Martin Olivo, MD,§ Jean Powers, MSc,§ Lesley Seymour, MD,§ and Penelope A. Bradbury, MD§
*Department of Oncology, McMaster University, Juravinski Cancer Centre, 
Hamilton Ontario, Canada; †Medical Oncology Department, Princess Margaret 
Cancer Centre, University Health Network, Toronto, Ontario, Canada; ‡Ottawa 
Hospital Cancer Centre, University of Ottawa, Ottawa, Ontario, Canada; and 
§NCIC CTG Queens University, Kingston, Ontario, Canada.
Disclosure: The authors declare no conflict of interest.
Address for correspondence: Peter Ellis, MD, PhD, Juravinski Cancer Centre, 
699 Concession St., Hamilton, ON L8V 5C2, Canada. E-mail: peter.
ellis@jcc.hhsc.ca
BRIEF REPORT
411Copyright © 2013 by the International Association for the Study of Lung Cancer
Journal of Thoracic Oncology ®  •  Volume 9, Number 3, March 2014 Phase I Trial of Dalotuzumab Plus Chemotherapy in ES SCLC
parameters. Treated brain metastases were allowed. The 
study (NCT00869752) was approved by the Ontario Cancer 
Research Ethics Board, and all patients provided written 
informed consent. A standard phase I design was used to define 
the recommended phase-two dose (RP2D) of dalotuzumab in 
combination with cisplatin (25mg/m2) and etoposide (100mg/
m2) administered intravenously on days 1 to 3 every 21 days. 
Two dose levels of dalotuzumab were planned (5mg/kg and 
10mg/kg intravenously administered weekly).  Dose-limiting 
toxicities (DLT) were defined as any of the following occur-
ring during cycle 1 of therapy: unexpected febrile neutrope-
nia or grade 4 neutropenia lasting more than 7 days; grade 
4 thrombocytopenia; grade 3 or 4 nonhematological toxici-
ties not usually observed with cisplatin and etoposide therapy 
(excluding alopecia, fatigue, grade 3 nausea, vomiting, diar-
rhea, or hyperglycemia); inability to administer cycle 2 within 
14 days of planned treatment. A minimum of three evalu-
able patients were planned at each dose level. If two or more 
DLTs were observed in the initial cohort, the dose of dalotu-
zumab could be de-escalated to 2.5mg/kg weekly. If one DLT 
was observed in the initial three patients, the cohort would 
be expanded to six evaluable patients. There were no plans 
to escalate the dose of dalotuzumab beyond the  single-agent 
RP2D of 10mg/kg weekly. Up to six additional patients were 
to be treated at the RP2D. The trial protocol initially included 
a phase 2 component at the RP2D of dalotuzumab, but this 
did not proceed because of a decision by Merck Frost to halt 
development of dalotuzumab in this setting.
Patients were treated with cisplatin, etoposide, and dalo-
tuzumab for a maximum of four to six cycles, with weekly 
dalotuzumab continued beyond this, until disease progres-
sion, unacceptable toxicity, or patient request to withdraw. 
Prophylactic cranial irradiation was allowed if indicated and 
dalotuzumab administration was interrupted during prophy-
lactic cranial irradiation. Disease status was determined after 
every second cycle of therapy and response to therapy deter-
mined by the investigator according to Response Evaluation 
Criteria in Solid Tumors 1.1. Adverse events were graded 
according to the National Cancer Institute Common Toxicity 
Criteria version 3.0. Serum to measure human-antihumanized 
antibody response to MK-0646 was collected at baseline and 
multiple time points in the study.
The primary outcome was determination of the RP2D. 
Secondary outcomes included assessment of objective 
response rate and toxicity. As there were only two planned 
dose levels, it was estimated that nine to 15 patients would be 
accrued to the phase I trial.
RESULTS
Twelve patients were enrolled in this phase I study 
 (DL1-3, DL2-9). Demographic characteristics are summa-
rized in Table 1. Two patients had small asymptomatic brain 
metastases at study entry. There were no DLTs observed 
during cycle 1 in either dose-escalation cohort. Therefore 
the RP2D of dalotuzumab was determined to be 10mg/kg 
weekly when combined with standard doses of cisplatin and 
etoposide. After determination of the RP2D, one DLT dur-
ing cycle 1 (grade 5 neutropenic sepsis) was observed in the 
expanded cohort at dose level 2. A second patient enrolled 
in the expanded dose level 2 cohort had a grade 3 syncopal 
event that was considered to be secondary to dehydration 
from the cisplatin chemotherapy. The objective response rate 
for the combination of cisplatin, etoposide, and dalotuzumab 
was 67% (8 partial response [PR], 2 stable disease [SD], 1 
progressive disease [PD], and 1 nonevaluable). Responses are 
summarized in a waterfall plot in Figure 1.
The addition of dalotuzumab to cisplatin and etoposide 
did not seem to affect the administered dose of chemotherapy. 
The median number of cycles of chemotherapy was four (range, 
3–6) in dose level 1 and five (range, 1–6) in dose level 2, and 
the median number of cycles of dalotuzumab was six (range, 
1–10) in both dose levels. There was no evidence of lower-dose 
intensity of cisplatin and etoposide with the higher-dose level 
of dalotuzumab (Table 2). The majority of patients (DL1, 2 and 
DL2, 7) experienced at least one dose delay of either chemo-
therapy or dalotuzumab. Neutropenia was the most common 
reason for chemotherapy dose delays with four delays occurring 
across the three patients treated at dose level 1 and seven occur-
rences across the nine patients treated at dose level 2.
Hematological toxicities occurred frequently (Table 3). 
Grade 3/4 neutropenia occurred in the majority of patients 
(92%) and grade 3/4 thrombocytopenia was also common 
(25%). There was one episode of febrile neutropenia and one 
episode of fatal neutropenic sepsis. All reported nonhemato-
logical toxicities are summarized in Table 3 (all grades ≥10%, 
or any grade 3/4 toxicity). The most frequent grade 3/4 nonhe-
matological toxicities were fatigue (33%), thrombosis (25%), 
and joint pain (17%). Grade 2 or 3 hyperglycemia occurred in 
one of three patients in dose level 1 and five of nine patients 
in dose level 2, suggesting this was a dose-dependent toxicity. 
One case of grade 3 hearing loss was attributed to cisplatin.
Seven serious adverse events (SAEs) related to one 
or more of the drugs in the protocol therapy were observed 
among three patients. One patient experienced neutropenic 
sepsis during cycle 1 and died. A second patient experienced 
an asymptomatic pulmonary embolism during cycle 2 and had 
a second SAE of febrile neutropenia during cycle 6. A third 
patient experienced four separate SAEs: chest discomfort 
and syncope during cycle 1; fatigue and stomach pain dur-
ing cycle 3; fatigue and cough during cycle 4; and fatigue, 
joint pain, and dyspnea while on single-agent dalotuzumab. 
TABLE 1.  Summary of Demographic Characteristics
Patient Characteristic Number
Number enrolled Dose level 1
Dose level 2
Expanded cohort
3
3
6
Median age 63 years (range, 48–70)
Sex Male
Female
6
6
Eastern Cooperative Oncology 
Group performance status
1
2
8
4
Prior radiotherapy 1
Number of sites of disease 3
≥4
4
8
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One additional SAE of back pain was considered unrelated to 
protocol therapy and secondary to disease progression. All 12 
patients had baseline serum collected, and all but one patient 
had two or more samples taken on treatment (median 4 time 
points). A total of 51 samples were analyzed for human-anti-
humanized antibody and all were negative.
DISCUSSION
This phase I trial demonstrated that dalotuzumab can be 
combined safely with standard doses of cisplatin and etopo-
side in patients with ES SCLC. With the exception of hyper-
glycemia, the toxicity of dalotuzumab in combination with 
chemotherapy was similar to what would be expected from 
cisplatin and etoposide alone. The dominant adverse events 
were hematological toxicities and fatigue. These toxicities 
are frequent in this patient population, which generally suf-
fers from multiple comorbidities and routinely experiences 
significant neutropenia with standard therapy. This study is 
in contrast to studies with other IGF-R inhibitors that have 
documented significant increases in hyperglycemia and asso-
ciated adverse events such as anorexia and dehydration.12 
Some dose-dependent hyperglycemia was observed, related to 
dalotuzumab therapy. However, dalotuzumab in combination 
with chemotherapy could be administered at its recommended 
phase 2 single-agent dose of 10mg/kg weekly and the addition 
of dalotuzumab did not seem to reduce the deliverable dose 
intensity of cisplatin or etoposide.
Despite the preclinical rationale for the importance of 
the IGF-R pathway in SCLC, the addition of dalotuzumab did 
not result in a clinically meaningful increase in response rate 
beyond what would be expected from cisplatin and etoposide 
alone.5 What is unclear is whether IGF-R suppression is an 
unsuccessful strategy in lung cancer in general, or whether 
this strategy should be evaluated in selected patients demon-
strating high levels of serum IGF.12 Unfortunately, there are 
too few patients in the current study to allow any meaningful 
biomarker analysis.
To date, studies of targeted agents have proven unsuc-
cessful in SCLC, despite biological rationale for their evalua-
tion.8 Inhibition of angiogenesis pathways,13,14 or proapoptotic 
FIGURE 1.  Waterfall plot of response to treatment.
TABLE 2.  Summary of Dose Intensity Data
Dose Level N
Cisplatin 
(25mg/m2/ 
week)
Etoposide 
(100mg/m2/ 
week Dalotuzumab
Dose level 1 
(5mg/kg/week)
3 19.6mg/m2/ 
week
78.5mg/m2/ 
week
3.9mg/kg/week
Dose level 2 
(10mg/kg/week)
9 20.7mg/m2/ 
week
85.9mg/m2/ 
week
7.6mg/kg/week
TABLE 3.  Summary of All Toxicities (All Grade and Grade 3/5)
All Grade Toxicities Grade 3–5 Toxicity
Hematological toxicity
  Anemia 12 (100%) 2 (17%)
  Neutropenia 11 (92%) 11 (92%)
  Leucopenia 11 (92%) 6 (50%)
  Thrombocytopenia 10 (83%) 3 (25%)
Nonhematological 
toxicity
  Fatigue 12 (100%) 4 (33%)
  Anorexia 8 (67%) 1 (8%)
  Nausea 10 (83%) 1 (8%)
  Vomiting 5 (42%) 0
  Mucositis 2 (17%) 1 (8%)
  Cough 11 (92%) 0
  Dyspnea 11 (92%) 1 (8%)
  Infection 3 (25%) 2 (17%, 1G5)a 
  Thrombosis 3 (25%) 3 (25%)
  Joint pain 5 (42%) 2 (17%)
  Pruritis 1 (8%) 1 (8%)
  Anxiety 4 (33%) 1 (8%)
  Depression 2 (17%) 1 (8%)
  Insomnia 4 (33%) 1 (8%)
  Allergic reaction 2 (17%) 1 (8%)
  Hearing loss 2 (17%) 1 (8%)
  Left ventricular 
dysfunction
1 (8%) 1 (8%)
  Syncope 1 (8%) 1 (8%)
aOne case of febrile neutropenia and one case of fatal neutropenic sepsis.
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pathways such as BCL 2,15 have failed to improve survival. In 
addition to increased serum vascular endothelial growth factor, 
abnormalities of cell-cycle regulators, such as P53 mutations 
and loss of the retinoblastoma gene occur frequently. Gene 
ampliication, or protein overexpression of  proto-oncogenes 
such as c-MYC and BCL-2 are also frequently observed in 
SCLC. Given the complexity of molecular abnormalities in 
SCLC, inhibition of a single molecular pathway may be an 
ineffective strategy. Novel approaches such as the combina-
tion of agents to inhibit more than one molecular pathway 
should be investigated.
ACKNOWLDEGMENT
The study was supported by the Canadian Cancer 
Society Research Institute (grant #021039).
REFERENCES
 1. American Cancer Society, Cancer Facts and Figures 2012. Atlanta: 
American Cancer Society. 2012.
 2. Shepherd FA, Crowley J, Van Houtte P, et al.; International Association 
for the Study of Lung Cancer International Staging Committee and 
Participating Institutions. The International Association for the Study of 
Lung Cancer lung cancer staging project: proposals regarding the clinical 
staging of small cell lung cancer in the forthcoming (seventh) edition of 
the tumor, node, metastasis classification for lung cancer. J Thorac Oncol 
2007;2:1067–1077.
 3. Chute JP, Chen T, Feigal E, Simon R, Johnson BE. Twenty years of phase 
III trials for patients with extensive-stage small-cell lung cancer: percep-
tible progress. J Clin Oncol 1999;17:1794–1801.
 4. Feld R, Evans WK, Coy P, et al. Canadian multicenter random-
ized trial comparing sequential and alternating administration of two 
 non-cross-resistant chemotherapy combinations in patients with limited 
small-cell carcinoma of the lung. J Clin Oncol 1987;5:1401–1409.
 5. Murray N, Livingston RB, Shepherd FA, et al. Randomized study of 
CODE versus alternating CAV/EP for extensive-stage small-cell lung 
cancer: an Intergroup Study of the National Cancer Institute of Canada 
Clinical Trials Group and the Southwest Oncology Group. J Clin Oncol 
1999;17:2300–2308.
 6. Niell HB, Herndon JE II, Miller AA, et al.; Cancer and Leukemia Group. 
Randomized phase III intergroup trial of etoposide and cisplatin with or 
without paclitaxel and granulocyte colony-stimulating factor in patients 
with extensive-stage small-cell lung cancer: Cancer and Leukemia Group 
B Trial 9732. J Clin Oncol 2005;23:3752–3759.
 7. Humblet Y, Symann M, Bosly A, et al. Late intensification chemo-
therapy with autologous bone marrow transplantation in selected 
small-cell carcinoma of the lung: a randomized study. J Clin Oncol 
1987;5:1864–1873.
 8. Blackhall FH, Shepherd FA. Small cell lung cancer and targeted thera-
pies. Curr Opin Oncol 2007;19:103–108.
 9. Quinn KA, Treston AM, Unsworth EJ, et al. Insulin-like growth factor 
expression in human cancer cell lines. J Biol Chem 1996;271:11477–11483.
 10. Izycki T, Chyczewska E, Naumnik W, Ossolinska M. Serum levels of 
IGF-I and IGFBP-3 in patients with lung cancer during chemotherapy. 
Oncol Res 2006;16:49–54.
 11. Scartozzi M, Bianconi M, Maccaroni E, Giampieri R, Berardi R, Cascinu 
S. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 
for the treatment of cancer. Curr Opin Mol Ther 2010;12:361–371.
 12. Jassem J, Langer CJ, Karp DD, et al. Randomized, open label, phase III 
trial of figitumumab in combination with paclitaxel and carboplatin ver-
sus paclitaxel and carboplatin in patients with non-small cell lung cancer 
(NSCLC). ASCO Meeting Abstracts 2010;28:7500.
 13. Arnold AM, Seymour L, Smylie M, et al.; National Cancer Institute of 
Canada Clinical Trials Group Study BR.20. Phase II study of vandetanib 
or placebo in small-cell lung cancer patients after complete or partial 
response to induction chemotherapy with or without radiation therapy: 
National Cancer Institute of Canada Clinical Trials Group Study BR.20. 
J Clin Oncol 2007;25:4278–4284.
 14. Lee S-M, Woll PJ, James LE, et al. A phase III randomised, double blind, 
placebo controlled trial of etoposide/carboplatin with or without thalido-
mide in advanced small cell lung cancer (SCLC): PRS-04. J Thor Oncol 
2007;2:S306–S7 10.1097/01.JTO.0000283089.56099.79.
 15. Langer CJ, Albert I, Kovacs P, et al. A randomized phase II study of carbo-
platin (C) and etoposide (E) with or without pan-BCL-2 antagonist oba-
toclax (Ob) in extensive-stage small cell lung cancer (ES-SCLC). ASCO 
Meeting Abstracts 2011;29:7001.
